🚨New Publication Alert: Our Landmark Study Published in the European Heart Journal! We’re proud to share that our latest study demonstrates that EchoGo® Amyloidosis, Ultromics’ FDA-cleared AI tool, significantly improves the detection of cardiac amyloidosis using a single echocardiographic video clip. 🫀 Cardiac amyloidosis is a frequently missed, life-threatening cause of heart failure. As new disease-modifying therapies emerge, early and accurate detection is more important than ever. 💡 EchoGo® Amyloidosis is: 💙 The first FDA-cleared AI screening tool for cardiac amyloidosis 💙 Granted Breakthrough Device designation 💙 Validated in a large, multi-center, international study (n = 2,719) 💙 Highly accurate with 85% sensitivity and 93% specificity across AL, ATTRwt, and ATTRv 💙 Demonstrated superior performance vs traditional scoring systems 🌍 The study involved 18 leading global centers including Mayo Clinic, University of Chicago, Brigham and Women’s, Columbia and more. This breakthrough shows the potential for AI to help clinicians detect cardiac amyloidosis earlier, differentiate it from similar conditions like HFpEF or hypertrophic cardiomyopathy, and expand access to life-changing therapies. This is another important milestone for @ultromics as we continue to transform cardiovascular care with AI — not just through EchoGo® Amyloidosis, but also through our EchoGo® Heart Failure platform. 🔗 Full Publication: academic.oup.com/eurheartj/a… With gratitude to our incredible collaborators: @pattypellikka @JSlivnickMD Will Hawkes @sarahcud @DocStrom @AshleyAkerman And a heartfelt tribute to the late Roberto Lang, whose leadership and vision helped make this work possible. His legacy continues through innovations like this ❤️ @ESC_Journals @escardio @ASE360 #EHJ #Echofirst #CardiacAmyloidosis #HeartFailure #AIinHealthcare #MedTech #Cardiology #DigitalHealth #EchoGo #Ultromics #Innovation #HFpEF #CardiovascularAI